Evidence map›Paper›PMID 39815075›Full record

ArticleAnnals of surgical oncology2025

Patients with DCIS Seen at a Specialized High-Risk Breast Clinic Run by Surgical Advanced Practice Providers Have High Rates of Preventive Medication Uptake.

Kathryn Paschalis, Chelsea Marin, Kendall Miller, Crystal Regis, Katie Bates, Jessica Gooch, Marilyn Ling, Jan Dombrowski, Brian Yirinec, Alissa Huston and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kathryn PaschalisDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Chelsea MarinDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Kendall MillerWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Crystal RegisDivision of Surgical Oncology, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Katie BatesDivision of Surgical Oncology, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Jessica GoochWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Marilyn LingWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Jan DombrowskiWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Brian YirinecWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Alissa HustonWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Anna WeissWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Anna_weiss@urmc.rochester.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreventative medication (PM) uptake is low among patients at an elevated risk of breast cancer, largely due to fears of intolerance. This study aimed to investigate whether a new, surgical advanced practice provider (APP)-run clinic was effectively prescribing PM. We hypothesized equivalent rates of PM uptake compared to consultation with medical oncologists (MD). PATIENTS AND

methodsThe APP-run clinic and accompanying database were initiated 01/2023, including patients with benign breast complaints and/or an elevated risk of invasive breast cancer. A historic single-institution surgical database and this prospective database were queried for patients with ductal carcinoma in situ between 04/2007-05/2023 and 01/2023-01/2024, respectively. Patients with invasive breast cancer within the prior 5 years were excluded. Chart review abstracted PM type/dose. Chi square analysis compared PM uptake rates and dose.

resultsA total of 523 patients met study criteria; the MD sample and APP sample were relatively well balanced except fewer hormone receptor positive patients in the MD sample (266/309 [86.1%] versus 202/214 [94.4%] APP, p < 0.01). PM uptake was lower in the MD sample (96/309 [31.1%] compared to the APP sample (86/214 [40.2%], p = 0.03). There was significantly more tamoxifen prescribed among the APP sample (58.2% vs. 35.6% among MD, p = 0.02), and low-dose tamoxifen prescribing increased significantly (47.3% vs. 9.8% MD, p < 0.01).

conclusionsOur surgical APP-run breast health clinic has demonstrated equivalent PM uptake as compared to patients seen previously by medical oncologists. This model should be considered broadly. Additionally, low-dose tamoxifen has become the prescription of choice; thus, long-term studies of tamoxifen 5 mg are warranted.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingPractice Patterns, Physicians'AdultAgedFemaleFollow-Up StudiesHumansMiddle AgedPrognosisProspective StudiesTamoxifenAntineoplastic Agents, HormonalTamoxifen

Identifiers

PMID39815075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.